Reassessment of the use of desferrioxamine B in iron overload
- PMID: 1272274
- DOI: 10.1056/NEJM197606242942603
Reassessment of the use of desferrioxamine B in iron overload
Abstract
Treatment of transfusion-induced iron overload by daily intramuscular injection of the chelator desferrioxamine has not produced impressive urinary iron excretion. We attempted to augment net iron excretion by altering both the route and quantity of chelator administered. Two ascorbic acid-replete patients excreted a mean of 14.5 mg of iron per 24 hours after a single intramuscular injection of 750 mg of desferrioxamine. Excretion increased to a mean of 44.9 mg when this dose was delivered by a continuous 24-hour intravenous infusion. When the intravenous dose of chelator was increased incrementally to as high as 16,000 mg per 24 hours, iron excretion increased up to 180 mg per day. At these high-dose levels, efficiency of binding of iron to chelator was compromised. Constant exposure of the labile iron pool to a chelating agent markedly enhances net iron excretion in splenectomized transfusion-dependent patients.
Similar articles
-
Desferrioxamine induced urinary iron excretion in thalassemia.Indian Pediatr. 1993 Jun;30(6):775-8. Indian Pediatr. 1993. PMID: 8132258
-
Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.Lancet. 1976 Dec 11;2(7998):1278-80. doi: 10.1016/s0140-6736(76)92035-3. Lancet. 1976. PMID: 63749 Clinical Trial.
-
[Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].Arch Fr Pediatr. 1980 Apr;37(4):241-7. Arch Fr Pediatr. 1980. PMID: 7406638 French.
-
Advances in the use of iron-chelating agents for the treatment of iron overload.Prog Hematol. 1979;11:267-312. Prog Hematol. 1979. PMID: 392593 Review. No abstract available.
-
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.Semin Hematol. 1995 Oct;32(4):304-12. Semin Hematol. 1995. PMID: 8560288 Review.
Cited by
-
Growth plate injury of the long bones in treated beta-thalassemia.Skeletal Radiol. 1992;21(1):39-44. doi: 10.1007/BF00243093. Skeletal Radiol. 1992. PMID: 1546335
-
A mathematical model of iron metabolism.J Math Biol. 1982;15(2):173-201. doi: 10.1007/BF00275072. J Math Biol. 1982. PMID: 7153668
-
Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.Eur J Pediatr. 1981 Nov;137(3):285-90. doi: 10.1007/BF00443259. Eur J Pediatr. 1981. PMID: 7318841
-
Pathophysiology and Clinical Manifestations of the β-Thalassemias.Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a011726. doi: 10.1101/cshperspect.a011726. Cold Spring Harb Perspect Med. 2012. PMID: 23209183 Free PMC article.
-
High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis.Blut. 1986 Apr;52(4):211-9. doi: 10.1007/BF00321080. Blut. 1986. PMID: 3634632
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources